Derangement of hemostasis in rheumatoid arthritis: Association with demographic, inflammatory and metabolic factors

Clinical Rheumatology

Volumn 32, Issue 9, 2013, Pages 1357-1364

  Dimitroulas, Theodoros ^a,e   Douglas, Karen M J ^a   Panoulas, Vasileios F ^a   Toms, Tracey ^a   Smith, Jacqueline P ^a   Treharne, Gareth J ^b   Nightingale, Peter ^c   Hodson, James ^c   Kitas, George D ^a,d  

^a DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Blood coagulation; Cardiovascular disease; Fibrinolysis; Rheumatoid arthritis

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTHROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ARTHRITIS, RHEUMATOID; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN; REGRESSION ANALYSIS; RISK FACTORS; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 84883240321     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2283-6     Document Type: Article

References (54)

1. Wolfe F, Freundlich B, Straus V (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36-40
2. Douglas KMJ, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, Bankd MJ, Kitas GD (2005) Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 65:348-353
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402-411
4. Barnhart MI, Riddle JM, Bluhm GB, Quintana C (1967) Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis 26:206-218
5. Busso N, Hamilton JA (2002) Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 46:2268-2279
6. Huber K (2001) Plasminogen activator inhibitor type-1 (part one), basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 11:183-193
7. Swiatkiewicz A, Jurkowski P, Kotschy M, Ciecierski M, Jawień A (2002) Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med Sci Monit 8:CR263-CR268
8. Yukizawa Y, Inaba Y, Watanabe S, Yajima S, Kobayashi N, Ishida T, Iwamoto N, Choe H, Saito T (2012) Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 83:14-21
9. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I (2009) D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27:4124-4129
10. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417-430
11. Hart DA, Fritzler MJ (1989) Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions. J Rheumatol 16:1184-1191
12. Kamper EF, Kopeikina LT, Trontzas P, Potamianou A, Tsiroglou E, Stavridis JC (2000) The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. J Rheumatol 11:2545-2550
13. Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I (1997) Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 16:254-260
14. Lau CS, McLaren M, Hanslip J, Kerr M, Belch JJ (1993) Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and imPAI-1red endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 52:643-649
15. Wållberg-Jonsson S, Trfunovic Cvetkovic J, Sundqvist KG, Rantapåå-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875-882
16. Wallberg-Jonsson S, Dahlén GH, Nilsson TK, Rånby M, Rantapaa-Dahlqvist S (1993) Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 12:318-324
17. Saxne T, Lecander I, Geborek P (1993) Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 20:91-96
18. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Péclat V, Gerster JC, Busso N (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1:2510-2515
19. Toms TE, Symmons DP, Kitas GD (2010) Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 8:301-326
20. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinoglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD (2007) Prevalence of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46:1477-1482
21. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 25:252-259
22. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM, Koutedakis Y, Kitas GD (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) 47:239-248
23. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD (2009) Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 11:R110
24. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Douglas KM, Nevill AM, Jamurtas AZ, Kita M, Koutedakis Y, Kitas GD (2009) Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68:242-245
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
26. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
27. Kirwan JR, Reeback JS (1986) Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206-209
28. Rose GA (1962) The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27:645-658
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
30. Expert Panel on Detection EaToHBCiA (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
31. Rudnicka AR, Rumley A, Lowe GDO, Strachan DP (2007) Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-Dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 15:996-1003
32. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GDO (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40:640-644
33. WHO MONICA Project Part III (1990) Population survey; Section 1: Population survey data component. MONICA manual. World Health Organisation, Geneva
34. Agirbasli M, Inanc N, Baykan OA, Direskeneli H (2006) The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 24:580-583
35. Wållberg-Jonsson S, Rantapää-Dahlqvist S, Nordmark L, Rånby M (1996) Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol 23:1704-1709
36. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799-1809
37. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB (1999) Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 159:237-245
38. Yarnell J, McCrum E, Rumley A, Patterson C, Salomaa V, Lowe G, Al E (2005) Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study{dagger}. Eur Heart J 26:332-342
39. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC (1998) Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79:129-133
40. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, Kitas GD (2008) Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47:1286-1298
41. Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765-2775
42. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD (2009) Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 16:188-194
43. Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 33:293-299
44. Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42:607-613
45. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD (2005) Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 7:1-24
46. Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF (2005) Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women. Thromb Haemost 94:1190-1195
47. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2004) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-1454
48. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB (1999) Thrombogenic factors and recurrent coronary events. Circulation 99:2517-2522
49. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk ofcardiovascular disease. The Framingham Study. JAMA 258:1183-1186
50. Kannel WB (2005) Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40:1215-1216
51. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH (1993) Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168
52. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737-2745
53. Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8-14
54. Robinson SD, Dawson P, Ludlam CA, Boon NA, Newby DE (2006) Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. Clin Sci (Lond) 110:353-360